Caris Life Sciences, Inc. Common Stock

CAINasdaqCIK 2019410Healthcare / Healthcare Providers & Servicesfiscal year ends December10 quarters since 2024

Revenue, Q3 FY2026
$275M
+27.0% on Q3 FY2025
Net income
$15M
−37.3% on Q3 FY2025
Free cash flow
−$40M
−171.8% on Q3 FY2025
Diluted EPS
$0.05
−37.5% on Q3 FY2025
Revenue, TTM
$1.0B
trailing four quarters
Net margin, TTM
9.2%
net income $96M
Free cash flow, TTM
$29M
$84M less $55M capex
Cash and equivalents
—
long-term debt $393M, Sep 30, 2026
Shares, 12-month change
+1.6%
287M shares, Sep 30, 2026
Buybacks, TTM
$31M
0.5% of market value
Dividends, TTM
—
no yield
Market value
$6.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Caris Life Sciences, Inc. Common Stock reported revenue of $275M, +27.0% on Q3 FY2025, and net income of $15M (−37.3%). Operating margin was 7.0%. Free cash flow, operating cash flow less capital expenditures, was −$40M (−$22M less $17M). Diluted earnings per share were $0.05.

Share price

Daily candlesticks from June 18, 2025 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

CAI daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $24.00 · H $24.37 · L $22.58 · C $23.04 · −3.84% on the dayOver the range: −5.19%, Nov 14, 2025 to Nov 13, 2026
$13$19$25$32$38Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 10 quarters

Q2 FY2024 to Q3 FY2026, through the filing of November 4, 2026.

Revenue and net incomeRevenueNet income
−$200M−$100M$0$100M$200M$300MQ2'24, Revenue: $100MQ2'24, Net income: −$66MQ2'24Q3'24, Revenue: $102MQ3'24, Net income: −$68MQ3'24Q4'24, Revenue: $130MQ4'24, Net income: −$37MQ4'24Q1'25, Revenue: $121MQ1'25, Net income: −$103MQ1'25Q2'25, Revenue: $181MQ2'25, Net income: −$72MQ2'25Q3'25, Revenue: $217MQ3'25, Net income: $24MQ3'25Q4'25, Revenue: $293MQ4'25, Net income: $82MQ4'25Q1'26, Revenue: $216MQ1'26, Net income: −$510KQ1'26Q2'26, Revenue: $264MQ2'26, Net income: −$637KQ2'26Q3'26, Revenue: $275MQ3'26, Net income: $15MQ3'26−$200M−$100M$0$100M$200M$300MQ2'24, Revenue: $100MQ2'24, Net income: −$66MQ2'24Q3'24, Revenue: $102MQ3'24, Net income: −$68MQ3'24Q4'24, Revenue: $130MQ4'24, Net income: −$37MQ4'24Q1'25, Revenue: $121MQ1'25, Net income: −$103MQ1'25Q2'25, Revenue: $181MQ2'25, Net income: −$72MQ2'25Q3'25, Revenue: $217MQ3'25, Net income: $24MQ3'25Q4'25, Revenue: $293MQ4'25, Net income: $82MQ4'25Q1'26, Revenue: $216MQ1'26, Net income: −$510KQ1'26Q2'26, Revenue: $264MQ2'26, Net income: −$637KQ2'26Q3'26, Revenue: $275MQ3'26, Net income: $15MQ3'26−$200M−$100M$0$100M$200M$300MQ2'24, Revenue: $100MQ2'24, Net income: −$66MQ2'24Q3'24, Revenue: $102MQ3'24, Net income: −$68MQ3'24Q4'24, Revenue: $130MQ4'24, Net income: −$37MQ4'24Q1'25, Revenue: $121MQ1'25, Net income: −$103MQ1'25Q2'25, Revenue: $181MQ2'25, Net income: −$72MQ2'25Q3'25, Revenue: $217MQ3'25, Net income: $24MQ3'25Q4'25, Revenue: $293MQ4'25, Net income: $82MQ4'25Q1'26, Revenue: $216MQ1'26, Net income: −$510KQ1'26Q2'26, Revenue: $264MQ2'26, Net income: −$637KQ2'26Q3'26, Revenue: $275MQ3'26, Net income: $15MQ3'26

Net income losses drawn in red.

Free cash flow
−$100M−$50M$0$50M$100MQ2'24Q3'24, Free cash flow: −$71MQ3'24Q4'24, Free cash flow: −$41MQ4'24Q1'25, Free cash flow: −$34MQ1'25Q2'25, Free cash flow: $6MQ2'25Q3'25, Free cash flow: $55MQ3'25Q4'25, Free cash flow: $40MQ4'25Q1'26, Free cash flow: $23MQ1'26Q2'26, Free cash flow: $6MQ2'26Q3'26, Free cash flow: −$40MQ3'26−$100M−$50M$0$50M$100MQ2'24Q3'24, Free cash flow: −$71MQ3'24Q4'24, Free cash flow: −$41MQ4'24Q1'25, Free cash flow: −$34MQ1'25Q2'25, Free cash flow: $6MQ2'25Q3'25, Free cash flow: $55MQ3'25Q4'25, Free cash flow: $40MQ4'25Q1'26, Free cash flow: $23MQ1'26Q2'26, Free cash flow: $6MQ2'26Q3'26, Free cash flow: −$40MQ3'26−$100M−$50M$0$50M$100MQ2'24Q3'24, Free cash flow: −$71MQ3'24Q4'24, Free cash flow: −$41MQ4'24Q1'25, Free cash flow: −$34MQ1'25Q2'25, Free cash flow: $6MQ2'25Q3'25, Free cash flow: $55MQ3'25Q4'25, Free cash flow: $40MQ4'25Q1'26, Free cash flow: $23MQ1'26Q2'26, Free cash flow: $6MQ2'26Q3'26, Free cash flow: −$40MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$250M$500M$750M$1.0BQ2'24Q3'24Q4'24, Cash and equivalents: $64MQ4'24, Long-term debt: $319MQ4'24Q1'25, Cash and equivalents: $31MQ1'25Q2'25, Cash and equivalents: $719MQ2'25, Long-term debt: $374MQ2'25Q3'25, Cash and equivalents: $753MQ3'25, Long-term debt: $376MQ3'25Q4'25, Cash and equivalents: $796MQ4'25, Long-term debt: $379MQ4'25Q1'26, Cash and equivalents: $820MQ1'26, Long-term debt: $381MQ1'26Q2'26, Long-term debt: $393MQ2'26Q3'26, Long-term debt: $393MQ3'26$0$250M$500M$750M$1.0BQ2'24Q3'24Q4'24, Cash and equivalents: $64MQ4'24, Long-term debt: $319MQ4'24Q1'25, Cash and equivalents: $31MQ1'25Q2'25, Cash and equivalents: $719MQ2'25, Long-term debt: $374MQ2'25Q3'25, Cash and equivalents: $753MQ3'25, Long-term debt: $376MQ3'25Q4'25, Cash and equivalents: $796MQ4'25, Long-term debt: $379MQ4'25Q1'26, Cash and equivalents: $820MQ1'26, Long-term debt: $381MQ1'26Q2'26, Long-term debt: $393MQ2'26Q3'26, Long-term debt: $393MQ3'26$0$250M$500M$750M$1.0BQ2'24Q3'24Q4'24, Cash and equivalents: $64MQ4'24, Long-term debt: $319MQ4'24Q1'25, Cash and equivalents: $31MQ1'25Q2'25, Cash and equivalents: $719MQ2'25, Long-term debt: $374MQ2'25Q3'25, Cash and equivalents: $753MQ3'25, Long-term debt: $376MQ3'25Q4'25, Cash and equivalents: $796MQ4'25, Long-term debt: $379MQ4'25Q1'26, Cash and equivalents: $820MQ1'26, Long-term debt: $381MQ1'26Q2'26, Long-term debt: $393MQ2'26Q3'26, Long-term debt: $393MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Caris Life Sciences, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Mar 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 12, 2025Q1 FY2025ended Mar 31, 2025filed Aug 12, 2025Q4 FY2024ended Dec 31, 2024filed Aug 12, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue275264216293217181121130+27.0%
Cost of revenue—————————
Gross profit—————————
Research and development3432313222252327+56.5%
Selling, general and administrative6967605752645243+33.3%
Operating income192758833(18)(58)(37)−40.8%
Other income (expense)(2)(28)(6)(6)(8)(54)(45)0+70.6%
Pretax income17(1)(1)8224(72)(103)(37)−30.6%
Income tax20000000—
Net income15(1)(1)8224(72)(103)(37)−37.3%
Diluted EPS ($)0.050.000.00—0.08(7.97)(3.57)—−37.5%
Diluted shares (millions)295283283—2976536——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Caris Life Sciences, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Mar 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 12, 2025Q1 FY2025ended Mar 31, 2025filed Aug 12, 2025Q4 FY2024ended Dec 31, 2024filed Aug 12, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents——8207967537193164—
Short-term investments1021022222—2+4392.0%
Total current assets1,0671,0581,014998854833—216+24.9%
Total assets1,2561,2301,1621,126985955—344+27.5%
Total current liabilities1591911441278690—165+84.8%
Long-term debt393393381379376374—319+4.5%
Total debt393393381379376374—373+4.6%
Total liabilities616638569548506502—621+21.7%
Stockholders’ equity639592593577478453(2,600)(2,499)+33.7%
Shares outstanding (millions)287283283283282281———

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Caris Life Sciences, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Mar 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 12, 2025Q1 FY2025ended Mar 31, 2025filed Aug 12, 2025Q4 FY2024ended Dec 31, 2024filed Aug 12, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(22)283345627(31)(39)−135.6%
Capital expenditures17221057132+146.2%
Free cash flow (CFO − capex)(40)62340556(34)(41)−171.8%
Depreciation and amortization77545679+34.7%
Share repurchases1021000000—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed March 3, 2026.

Income statement

Caris Life Sciences, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Mar 3, 2026FY2024ended Dec 31, 2024filed Aug 12, 2025FY2023ended Dec 31, 2023filed Aug 12, 2025
Revenue812412306
Cost of revenue———
Gross profit———
Research and development102114117
Selling, general and administrative225169149
Operating income45(257)(320)
Other income (expense)(113)(25)(22)
Pretax income(68)(282)(341)
Income tax000
Net income(68)(282)(341)
Diluted EPS ($)(3.22)(10.66)(13.24)
Diluted shares (millions)1673535

Balance sheet

Caris Life Sciences, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Mar 3, 2026FY2024ended Dec 31, 2024filed Aug 12, 2025FY2023ended Dec 31, 2023filed Aug 12, 2025
Cash and equivalents79664—
Short-term investments22—
Total current assets998216—
Total assets1,126344—
Total current liabilities127165—
Long-term debt379319—
Total debt379373—
Total liabilities548621—
Stockholders’ equity577(2,499)(2,145)
Shares outstanding (millions)283——

Cash flow statement

Caris Life Sciences, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Mar 3, 2026FY2024ended Dec 31, 2024filed Aug 12, 2025FY2023ended Dec 31, 2023filed Aug 12, 2025
Operating cash flow83(245)(276)
Capital expenditures16822
Free cash flow (CFO − capex)67(254)(298)
Depreciation and amortization234949
Share repurchases000
Dividends paid———

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$27M
5 sales by 3 insiders; officers and directors $27M
Bought, twelve months
$1M
2 purchases by 2 insiders; officers and directors $1M
Sold, twelve months
$29M
7 sales by 4 insiders; officers and directors $29M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 22, 2026Denton John RusselSee Remarksopen-market sale7,500$31.82$239K174,855Sep 23, 2026
Sep 17, 2026Brille Brian JSee Remarks, Directoroption exercise400,000$2.44$976K630,303Sep 17, 2026
Sep 17, 2026Brille Brian JSee Remarks, Directoropen-market sale400,000$30.33$12M230,303Sep 17, 2026
Sep 4, 2026Spetzler David BaxleyPresidentoption exercise250,000$2.44$610K1MSep 4, 2026
Sep 4, 2026Spetzler David BaxleyPresidentopen-market sale119,212$24.76$3M1MSep 4, 2026
Sep 3, 2026Spetzler David BaxleyPresidentoption exercise1M$2.44$2M2MSep 4, 2026
Sep 3, 2026Spetzler David BaxleyPresidentopen-market sale393,100$24.76$10M1MSep 4, 2026
Sep 3, 2026Spetzler David BaxleyPresidentopen-market sale84,900$25.32$2M1MSep 4, 2026
Aug 14, 2026Castleman Peter MDirectoraward13,192$0.00—29,321Aug 14, 2026
Aug 14, 2026Phillips T DannyDirectoraward13,192$0.00—133,060Aug 14, 2026
Aug 14, 2026Minor LloydDirectoraward13,192$0.00—31,813Aug 14, 2026
Aug 14, 2026Gilliam Joseph EDirectoraward13,192$0.00—29,321Aug 14, 2026
Aug 14, 2026Fredrickson David PaulDirectoraward13,192$0.00—31,813Aug 14, 2026
Aug 14, 2026Vacirca Jeff LDirectoraward13,192$0.00—62,863Aug 14, 2026
Aug 14, 2026Johansen Laura IDirectoraward13,192$0.00—343,897Aug 14, 2026
Aug 14, 2026Halbert JonDirectoraward13,192$0.00—131,813Aug 14, 2026
May 29, 2026Poste GeorgeDirectoraward1,600$15.62$25K17,729Jun 2, 2026
May 29, 2026Knowles Jonathan Kenneth CharlesDirectoraward1,600$15.62$25K308,979Jun 2, 2026
May 15, 2026Halbert JonDirectoropen-market buyindirect68,000$14.56$990K704,598Jul 13, 2026
May 15, 2026Denton John RusselSee Remarkstax withholding6,047$15.25$92K181,515May 18, 2026
May 15, 2026Power Luke ThomasSee Remarkstax withholding9,771$15.25$149K153,771May 18, 2026
May 15, 2026Spetzler David BaxleyPresidenttax withholding13,856$15.25$211K530,083May 18, 2026
May 15, 2026Brille Brian JSee Remarks, Directortax withholding13,987$15.25$213K230,303May 18, 2026
May 15, 2026Halbert David DSee Remarks, Director, 10% ownertax withholding40,712$15.25$621K3MMay 18, 2026
May 11, 2026Vacirca Jeff LDirectoropen-market buy31,050$16.15$501K49,671May 12, 2026

Full insider history for Caris Life Sciences, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held CAI in their latest 13F filing, through November 12, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded CAI by quarter.

FundManagerQuarterValueSharesWeightMove
Renaissance TechnologiesPeter BrownQ3 2026$20M656,5000.03%added +15.6%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CARIS LIFE SCIENCES, INC., CIK 2019410 on EDGAR
Extract generated
November 16, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total debt: LongTermDebt, noncurrent+current
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/CAI.json